Tempest Announces Successful End-of-Phase 2 Meeting With FDA for Amezalpat (Tpst-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest宣佈與FDA成功結束2期會議,使用Amezalpat(Tpst-1120)治療一線肝細胞癌。
Tempest Announces Successful End-of-Phase 2 Meeting With FDA for Amezalpat (Tpst-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest宣佈與FDA成功結束2期會議,使用Amezalpat(Tpst-1120)治療一線肝細胞癌。
譯文內容由第三人軟體翻譯。